Thromb Haemost 2023; 123(01): 006-015
DOI: 10.1055/s-0042-1758128
Review Article

How Did We Get Here? Antithrombotic Therapy after Bioprosthetic Aortic Valve Replacement: A Review

Rachel Eikelboom
1   Department of Surgery, University of Manitoba, Max Rady College of Medicine, Winnipeg, Manitoba, Canada
,
Richard P. Whitlock
2   Division of Cardiac Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada
,
Renato D. Lopes
3   Division of Cardiology, Duke Clinical Research Institute, Duke University, Durham, North Carolina, United States
,
Deborah Siegal
4   Department of Medicine, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
,
Iqbal H. Jaffer
2   Division of Cardiac Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada
,
Paul Drakos
5   Department of Kinesiology, McMaster University, Hamilton, Ontario, Canada
,
6   Division of Hematology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
,
Emilie P. Belley-Côté
7   Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
› Institutsangaben

Abstract

Importance Aortic stenosis is the most common valvular disease, and more than 90% of patients who undergo aortic valve replacement receive a bioprosthetic valve. Yet optimal antithrombotic therapy after bioprosthetic aortic valve replacement remains uncertain, and guidelines provide contradictory recommendations.

Observations Randomized studies of antithrombotic therapy after bioprosthetic aortic valve replacement are small and underpowered. Observational data present opposing, and likely confounded, results. Historically, changes to guidelines have not been informed by high-quality new data. Current guidelines from different professional bodies provide contradictory recommendations despite citing the same evidence.

Conclusion Insufficient antithrombotic therapy after bioprosthetic aortic valve replacement has serious implications: ischemic stroke, systemic arterial thromboembolism, and clinical and subclinical valve thromboses. Unnecessarily intense antithrombotic therapy, however, increases risk of bleeding and associated morbidity and mortality. Professional bodies have used the current low-quality evidence and generated incongruent recommendations. Researchers should prioritize generating high-quality, randomized evidence evaluating the risks and benefits of antiplatelet versus anticoagulant therapy after bioprosthetic aortic valve replacement.



Publikationsverlauf

Eingereicht: 17. Juni 2022

Angenommen: 19. September 2022

Artikel online veröffentlicht:
13. Dezember 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 D'Agostino RS, Jacobs JP, Badhwar V. et al. The Society of Thoracic Surgeons Adult Cardiac Surgery Database: 2019 update on outcomes and quality. Ann Thorac Surg 2019; 107 (01) 24-32
  • 2 Carroll JD, Mack MJ, Vemulapalli S. et al. STS-ACC TVT registry of transcatheter aortic valve replacement. J Am Coll Cardiol 2020; 76 (21) 2492-2516
  • 3 Puri R, Auffret V, Rodés-Cabau J. Bioprosthetic valve thrombosis. J Am Coll Cardiol 2017; 69 (17) 2193-2211
  • 4 Baumgartner H, Falk V, Bax JJ. et al; ESC Scientific Document Group. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 2017; 38 (36) 2739-2791
  • 5 Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis. Chest 2012; 141 (2, Suppl): e576S-e600S
  • 6 Otto CM, Nishimura RA, Bonow RO. et al; Writing Committee Members. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2021; 77 (04) e25-e197
  • 7 Ross DN. Homograft replacement of the aortic valve. Lancet 1962; 2 (7254): 487
  • 8 Barratt-Boyes BG. Homograft aortic valve replacement in aortic incompetence and stenosis. Thorax 1964; 19 (02) 131-150
  • 9 Binet JP, Carpentier A, Langlois J, Duran C, Colvez P. Implantation of heterogenic valves in the treatment of aortic cardiopathies [in French]. C R Acad Hebd Seances Acad Sci D 1965; 261 (25) 5733-5734
  • 10 Ionescu MI, Pakrashi BC, Holden MP, Mary DA, Wooler GH. Results of aortic valve replacement with frame-supported fascia lata and pericardial grafts. J Thorac Cardiovasc Surg 1972; 64 (03) 340-353
  • 11 David TE, Ropchan GC, Butany JW. Aortic valve replacement with stentless porcine bioprostheses. J Card Surg 1988; 3 (04) 501-505
  • 12 Macmanus Q, Grunkemeier G, Thomas D, Lambert LE, Starr A. The Starr-Edwards model 6000 valve. A fifteen-year follow-up of the first successful mitral prosthesis. Circulation 1977; 56 (4, Pt 1): 623-625
  • 13 Sullivan JM, Harken DE, Gorlin R. Pharmacologic control of thromboembolic complications of cardiac-valve replacement. N Engl J Med 1971; 284 (25) 1391-1394
  • 14 Barratt-Boyes BG, Lowe JB, Cole DS, Kelly DT. Homograft valve replacement for aortic valve disease. Thorax 1965; 20 (06) 495-504
  • 15 Angell WW, Angell JD. Porcine valves. Prog Cardiovasc Dis 1980; 23 (02) 141-166
  • 16 Heras M, Chesebro JH, Fuster V. et al. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 1995; 25 (05) 1111-1119
  • 17 Nuñez L, Gil Aguado M, Larrea JL, Celemín D, Oliver J. Prevention of thromboembolism using aspirin after mitral valve replacement with porcine bioprosthesis. Ann Thorac Surg 1984; 37 (01) 84-87
  • 18 Chesebro JH, Adams PC, Fuster V. Antithrombotic therapy in patients with valvular heart disease and prosthetic heart valves. J Am Coll Cardiol 1986; 8 (6, Suppl B): 41B-56B
  • 19 Jaffer IH, Fredenburgh JC, Hirsh J, Weitz JI. Medical device-induced thrombosis: what causes it and how can we prevent it?. J Thromb Haemost 2015; 13 (Suppl 1): S72-S81
  • 20 Jaffer IH, Stafford AR, Fredenburgh JC, Whitlock RP, Chan NC, Weitz JI. Dabigatran is less effective than warfarin at attenuating mechanical heart valve-induced thrombin generation. J Am Heart Assoc 2015; 4 (08) e002322
  • 21 Dangas GD, Weitz JI, Giustino G, Makkar R, Mehran R. Prosthetic heart valve thrombosis. J Am Coll Cardiol 2016; 68 (24) 2670-2689
  • 22 Noble S, Asgar A, Cartier R, Virmani R, Bonan R. Anatomo-pathological analysis after CoreValve Revalving system implantation. EuroIntervention 2009; 5 (01) 78-85
  • 23 Pislaru SV, Hussain I, Pellikka PA. et al. Misconceptions, diagnostic challenges and treatment opportunities in bioprosthetic valve thrombosis: lessons from a case series. Eur J Cardiothorac Surg 2015; 47 (04) 725-732
  • 24 Dohi M, Doi K, Yaku H. Early stenosis of an aortic porcine bioprosthesis due to thrombosis: case report and literature review. J Thorac Cardiovasc Surg 2015; 149 (06) e83-e86
  • 25 Brown ML, Park SJ, Sundt TM, Schaff HV. Early thrombosis risk in patients with biologic valves in the aortic position. J Thorac Cardiovasc Surg 2012; 144 (01) 108-111
  • 26 Musumeci L, Jacques N, Hego A, Nchimi A, Lancellotti P, Oury C. Prosthetic aortic valves: challenges and solutions. Front Cardiovasc Med 2018; 5: 46
  • 27 An KR, Belley-Cote EP, Um KJ. et al. Antiplatelet therapy versus anticoagulation after surgical bioprosthetic aortic valve replacement: a systematic review and meta-analysis. Thromb Haemost 2019; 119 (02) 328-339
  • 28 Egbe AC, Pislaru SV, Pellikka PA. et al. Bioprosthetic valve thrombosis versus structural failure: clinical and echocardiographic predictors. J Am Coll Cardiol 2015; 66 (21) 2285-2294
  • 29 Makkar RR, Fontana G, Jilaihawi H. et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med 2015; 373 (21) 2015-2024
  • 30 Blanke P, Leipsic JA, Popma JJ. et al; Evolut Low Risk LTI Substudy Investigators. Bioprosthetic aortic valve leaflet thickening in the evolut low risk sub-study. J Am Coll Cardiol 2020; 75 (19) 2430-2442
  • 31 Chakravarty T, Søndergaard L, Friedman J. et al; RESOLVE; SAVORY Investigators. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet 2017; 389 (10087): 2383-2392
  • 32 Makkar RR, Blanke P, Leipsic J. et al. Subclinical leaflet thrombosis in transcatheter and surgical bioprosthetic valves: PARTNER 3 cardiac computed tomography substudy. J Am Coll Cardiol 2020; 75 (24) 3003-3015
  • 33 Hansson NC, Grove EL, Andersen HR. et al. Transcatheter aortic valve thrombosis: incidence, predisposing factors, and clinical implications. J Am Coll Cardiol 2016; 68 (19) 2059-2069
  • 34 Zoghbi WA, Chambers JB, Dumesnil JG, Foster E, Gottdiener JS, Grayburn PA, Khandheria BK, Levine RA, Marx GR, Miller Jr FA, Nakatani S, Quiñones MA, Rakowski H, Rodriguez LL, Swaminathan M, Waggoner AD, Weissman NJ, Zabalgoitia M. American Society of Echocardiography's Guidelines and Standards Committee, Task Force on Prosthetic Valves, American College of Cardiology Cardiovascular Imaging Committee, Cardiac Imaging Committee of the American Heart Association, European Association of Echocardiography, European Society of Cardiology, Japanese Society of Echocardiography, Canadian Society of Echocardiography, American College of Cardiology Foundation, American Heart Association, European Association of Echocardiography, European Society of Cardiology, Japanese Society of Echocardiography, Canadian Society of Echocardiography. Recommendations for evaluation of prosthetic valves with echocardiography and doppler ultrasound: a report From the American Society of Echocardiography's Guidelines and Standards Committee and the Task Force on Prosthetic Valves, developed in conjunction with the American College of Cardiology Cardiovascular Imaging Committee, Cardiac Imaging Committee of the American Heart Association, the European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography and the Canadian Society of Echocardiography, endorsed by the American College of Cardiology Foundation, American Heart Association, European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography, and Canadian Society of Echocardiography. J Am Soc Echocardiogr 2009; 22 (09) 975-1014 , quiz 1082–1084
  • 35 Stewart WJ. Thrombosis of bioprosthetic valves: can we afford to ignore it?. J Am Coll Cardiol 2015; 66 (21) 2295-2297
  • 36 Gaudino M, Rahouma M, Di Mauro M. et al. Early versus delayed stroke after cardiac surgery: a systematic review and meta-analysis. J Am Heart Assoc 2019; 8 (13) e012447
  • 37 Brennan JM, Edwards FH, Zhao Y. et al; DEcIDE AVR Research Team. Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. J Am Coll Cardiol 2012; 60 (11) 971-977
  • 38 Ruel M, Kulik A, Lam BK. et al. Long-term outcomes of valve replacement with modern prostheses in young adults. Eur J Cardiothorac Surg 2005; 27 (03) 425-433 , discussion 433
  • 39 Chiang YP, Chikwe J, Moskowitz AJ, Itagaki S, Adams DH, Egorova NN. Survival and long-term outcomes following bioprosthetic vs mechanical aortic valve replacement in patients aged 50 to 69 years. JAMA 2014; 312 (13) 1323-1329
  • 40 Woldendorp K, Doyle MP, Black D. et al. Subclinical valve thrombosis in transcatheter aortic valve implantation: a systematic review and meta-analysis. J Thorac Cardiovasc Surg 2021; 162 (05) 1491.e2-1499 .e2
  • 41 Yanagawa B, Mazine A, Bhatt DL. et al. Subclinical bioprosthetic aortic valve thrombosis: clinical and translational implications. Curr Opin Cardiol 2017; 32 (02) 137-146
  • 42 Dangas GD, Tijssen JGP, Wöhrle J. et al; GALILEO Investigators. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med 2020; 382 (02) 120-129
  • 43 Collet JP, Berti S, Cequier A. et al. Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: the randomized ATLANTIS trial. Am Heart J 2018; 200: 44-50
  • 44 Brouwer J, Nijenhuis VJ, Rodés-Cabau J. et al. Aspirin alone versus dual antiplatelet therapy after transcatheter aortic valve implantation: a systematic review and patient-level meta-analysis. J Am Heart Assoc 2021; 10 (08) e019604
  • 45 Guimarães HP, Lopes RD, de Barros E Silva PGM. et al; RIVER Trial Investigators. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med 2020; 383 (22) 2117-2126
  • 46 Shim CY, Seo J, Kim YJ. et al; Explore the Efficacy and Safety of Edoxaban in Patients after Heart Valve Repair or Bioprosthetic Valve Replacement (ENAVLE) study group. Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: a randomized clinical trial. J Thorac Cardiovasc Surg 2023; 165 (01) 58-67
  • 47 Giugliano RP, Ruff CT, Braunwald E. et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22) 2093-2104
  • 48 Belley-Cote EPW. The Direct Oral Anticoagulation Versus Warfarin After Cardiac Surgery Trial (DANCE). ClinicalTrials.gov identifier: NCT04284839. Accessed March 22, 2021 at: https://clinicaltrials.gov/ct2/show/NCT04284839
  • 49 Fanaroff AC, Califf RM, Windecker S, Smith Jr SC, Lopes RD. Levels of evidence supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018. JAMA 2019; 321 (11) 1069-1080
  • 50 Babin-Ebell J, Schmidt W, Eigel P, Elert O. Aortic bioprosthesis without early anticoagulation–risk of thromboembolism. Thorac Cardiovasc Surg 1995; 43 (04) 212-214
  • 51 Aramendi JL, Agredo J, Llorente A, Larrarte C, Pijoan J. Prevention of thromboembolism with ticlopidine shortly after valve repair or replacement with a bioprosthesis. J Heart Valve Dis 1998; 7 (06) 610-614
  • 52 Cohn LH, Mudge GH, Pratter F, Collins Jr JJ. Five to eight-year follow-up of patients undergoing porcine heart-valve replacement. N Engl J Med 1981; 304 (05) 258-262
  • 53 Blair KL, Hatton AC, White WD. et al. Comparison of anticoagulation regimens after Carpentier-Edwards aortic or mitral valve replacement. Circulation 1994; 90 (5, Pt 2): II214-II219
  • 54 Gherli T, Colli A, Fragnito C. et al. Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study. Circulation 2004; 110 (05) 496-500
  • 55 Sundt TM, Zehr KJ, Dearani JA. et al. Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement?. J Thorac Cardiovasc Surg 2005; 129 (05) 1024-1031
  • 56 Aramendi JI, Mestres CA, Martinez-León J, Campos V, Muñoz G, Navas C. Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac): prospective, randomized, co-operative trial. Eur J Cardiothorac Surg 2005; 27 (05) 854-860
  • 57 Colli A, Mestres CA, Castella M, Gherli T. Comparing warfarin to aspirin (WoA) after aortic valve replacement with the St. Jude Medical Epic heart valve bioprosthesis: results of the WoA Epic pilot trial. J Heart Valve Dis 2007; 16 (06) 667-671
  • 58 Mérie C, Køber L, Skov Olsen P. et al. Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. JAMA 2012; 308 (20) 2118-2125
  • 59 Rafiq S, Steinbrüchel DA, Lilleør NB. et al. Antithrombotic therapy after bioprosthetic aortic valve implantation: warfarin versus aspirin, a randomized controlled trial. Thromb Res 2017; 150: 104-110
  • 60 Collet JP, Van Belle E, Thiele H. et al; ATLANTIS Investigators of the ACTION Group. Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. Eur Heart J 2022; 43 (29) 2783-2797
  • 61 Navarese EP, Zhang Z, Kubica J. et al; a Joint Effort of the Italian and Polish Cardiac Interventional Societies. Development and validation of a practical model to identify patients at risk of bleeding after TAVR. JACC Cardiovasc Interv 2021; 14 (11) 1196-1206